65,437 trials
ER+ Breast Cancer
Primary: Clinical Benefit Rate (CBR) — 15.4 percentage of participants
Non-alcoholic Steatohepatitis · Fatty Liver · Fibrosis, Liver
Primary: Number of NTZ Treated Participants Presenting Any Treatment Emergent Adverse Event (TEAE) — 20; 7; 10; 3 Participants
Breast Cancer
Primary: Support Care Needs Survey (SCNS) Score — 84.15; 85.01; 79.27; 78.20 score on a scale
Bipolar Disorder · Bipolar Depression · Unipolar Depression
Primary: Post-Lithium Treatment Hamilton Depression Rating Scale (HDRS) — -44.49 Percent Change in HDRS-24 Score
COVID-19
Primary: Lanadelumab Sub-protocol: Time to Confirmed Clinical Recovery Without Rehospitalization Through Day 29 — 10.0; 15.5 days — p=0.6672
Celiac Disease
Primary: Baseline Gastrointestinal Symptom Rating Scale (GSRS) Score — 2.7; 2.8 Score on a scale
Glaucoma, Open-Angle
Primary: Mean Retinal Sensitivity From Two Machines — 29.9; 24.8; 28.7; 22.9 decibels
Corona Virus Infection · Acute Respiratory Distress Syndrome · SARS-CoV Infection
Primary: Difference in Estimated (PEEP Adjusted) P/F Ratio at 7 Days — 281.4; 260.9 ratio
Glioblastoma
Primary: Number of Dose Limiting Toxicities — 0 Events meeting DLT Criteria
Solid Tumors · Non-small Cell Lung Cancer · Castration Resistant Prostate Cancer
Primary: Objective Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) — 3.9; 1.9 Percentage of participants
Recurrent Glioblastoma
Primary: Percentage of Participants With Drug-Related Adverse Events Leading to Discontinuation by Worst CTC Grade for All Treated Participants in Cohorts 1, 1b, 1c and 1d Who…
Respiratory Syncytial Virus Infections
Primary: Number of Participants With Any Solicited Administration Site Adverse Events (AEs) — 1; 6; 5; 21 Participants
Non-small Cell Lung Cancer
Primary: Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) Assessed by Independent Review Committee (IRC) — 7.0; 11.1…
Psoriasis
Primary: Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 12 — -1.6; -2.2; -1.4; -2.2 Unit on a scale — p=0.1641
Fabry Disease
Primary: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.03 — 21; 19; 4; 4 participants